Tao Synergies Inc. · NASDAQ:TAOX
Tao Synergies — NanoVibronix — IPO Roadshow (September 2017)
24 slides from Tao Synergies's IPO roadshow presentation, Sep 27, 2017
Slide 1: Investor Presentation September 2017
Investor Presentation September 2017 OTC QB : NAOV Issuer Free Writing Prospectus Filed Pursuant to Rule 433 of the Securities Act of 1933, as amended Registration Statement No. 333 - 218871
Slide 2: Safe Harbor
OTC QB : NAOV 2 Safe Harbor This presentation may contain “forward - looking statements” that are made pursuant to the “safe harbor” provisions as defined within the Private Securities Litigation Reform Act of 1995 . Forward - looking statements may be identified by words including “anticipates,” “b
Slide 3: Free Writing Prospectus
This presentation highlights basic information about NanoVibronix , Inc. and the offering. NanoVibronix , Inc. has filed a registration statement on Form S - 1 (Registration No. 333 - 218871) (including a prospectus) with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to wh
Slide 4: Key Highlights
OTC QB : NAOV 4 Key Highlights x Addresses multi - billion $ markets - catheter infections, pain relief & wound healing x New senior management team; previously introduced medical devices generating $ billions in sales; previously Kinetics Concepts (KCI) sold for $6B in 2011 x NanoVibronix was selec
Slide 5: Management and Board
OTC QB : NAOV Brian Murphy, CEO – Led the initiative for V.A.C. therapy into the homecare market from $0 - $400 million in 6 years at Kinetics Concepts (KCI) USA – Experience includes 30+ years in medical device and biologics industry – Leadership positions with MiMedx , KCI/ Acelity , ConvaTec , O2
Slide 6: What We Do
OTC QB: NAOV Surface Acoustic Wave (SAW) Technology : therapeutic ultrasound – Delivered through miniature transducers that transmit low - frequency, low - intensity ultrasound to induce repair of soft tissue and prevent bacterial colonization – Indicated for indwelling catheter infection, resolutio
Slide 7: Differentiated Technology
OTC QB: NAOV The NanoVibronix “Shield” platform delivers surface acoustic waves (SAW) to soft tissue , muscle , and indwelling devices is designed to : – Prevent microbial colonization and disrupts biofilm formation on indwelling devices – Provide a unique enhancement for antibiotic effectiveness –
Slide 8: Business Model – Recurring Revenue
Recurring revenue business model; driver and ongoing disposable transducer sales ● Re - usable driver device and disposable single patient use transducer ● Assumed consumer sales prices Consumer Price Nano ASP – Reusable Driver Device $395 $240 – $39 per disposable $39 $19 ● Distributor margins ~40%
Slide 9: UroShield
OTC QB: NAOV ● A therapeutic surface acoustic wave device, consisting of a reusable driver unit and a clamp - on disposable, which contains a proprietary therapeutic transducer ● D esigned to prevent bacterial docking, colonization and biofilm on indwelling urinary catheters, decrease UT and urine i
Slide 10: UroShield – Market Opportunity
OTC QB : NAOV – The Global Catheter market : $26. 6 B in 201 5; growing at an estimated 9.7% through 202 1; – 100 million foley catheters sold worldwide annually, with 25 million in the U.S.; represents a multi - billion dollar opportunity ● Urinary Tract Infections (UTI) account for more than 40% o
Slide 11: UroShield - Competitive Advantage
OTC QB : NAOV Disposable clip - on accessory for urinary catheter, designed to prevent urinary catheter related complications ● Prevents bacterial colonization and biofilm formation ● Prevents blockage of the catheter ● Prevention of bacterial infection - UTI ● Reduces pain, spasm, discomfort and tr
Slide 12: UroShield - Initial Foundational Validation
OTC QB: NAOV In Vivo Urinary Catheter Studies (Rabbits) ● Foundational, initial evaluation utilizing low level ultrasound, comparing the result to standard catheter without low level ultrasound. ● Evaluated both arms for biofilm formation, urinary tract infections & bacteriuria ● Non - vibrated cath
Slide 13: UroShield - Clinical Validation
UroShield - Clinical Validation OTC QB: NAOV 13 Case Studies & RCT’s ● Salem Academic Hospital HD1 - Double Blind, RCT, (22 patients) - statistically significant proof of prevention of biofilm, - less medications and less pain than the control ( U.Ikinger ) ● Salem Academic Hospital HD2 - Double Bli
Slide 14: UroShield – Successful Interim Trial Results
UroShield – Successful Interim Trial Results OTC QB: NAOV 14 Current Randomized Trial (60 patients) ● 22 subjects evaluated at two skilled nursing facilities near Buffalo, NY 11 patients treated with placebo devices (“controlled”) 11 patients had active UroShield devices (“treatment”) ● All exhibite
Slide 15: Market Preparation and Strategy
OTC QB : NAOV 15 Market Preparation and Strategy Market Strategy US Clinical and Regulatory ● Target completion of randomized trial in 1Q 2018 ● Expect trial results compiled and 510(K) Class 2 filing to FDA in 2Q 2018 ● Target FDA approval of 510K in 3Q 2018 ● Projected target US launch in 3 - 4Q 2
Slide 16: PainShield
OTC QB : NAOV A patch - based therapeutic Surface Acoustic Wave reusable driver unit and a disposable transducer patch T reats pain in nerves, muscles, joints and soft tissue through delivery of a localized ultrasound , and induce s soft tissue healing in targeted area s. 16 PainShield FDA Cleared,
Slide 17: PainShield – Market Opportunity
OTC QB : NAOV Trigeminal Neuralgia – A chronic pain condition of the most widely distributed 5 th cranial nerve in the head – Potentially as many as 280,000 sufferers in the U.S. & 7,000,000 worldwide. 15% growth estimated between 2012 and 2022 – Current treatments include opioid and surgical interv
Slide 18: PainShield – Targeted Marketing Strategy
OTC QB: NAOV 18 PainShield – Targeted Marketing Strategy ● Treats the source of the pain ● Alleviate pain Pain Management: - Chiropractic - Physical therapy - Sports medicine ● 73% of pts. achieving complete or near complete relief ● Definitive study planned Trigeminal Neuralgia ● Pain ● RX abuse &
Slide 19: WoundShield
OTC QB : NAOV A patch - based therapeutic surface acoustic wave unit, consisting of the reusable driver unit and a disposable patch, incorporating a proprietary therapeutic transducer F acilitates tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tis
Slide 20: WoundShield – Status & Strategy
OTC QB: NAOV Disposable, patch based therapeutic ultrasound device ● Induces perfusion in soft tissue for wound healing ● Encourages epithelial tissue growth and migration ● Accelerates healing of chronic and acute wounds ● Hands - free, portable and easy to use ● For use in both clinical and home s
Slide 21: Product Pipeline
Product Pipeline OTC QB : NAOV 21 ● LungShield ™ , SAW ultrasound device to manage biofilm adhesion and infection in endotracheal tubes. LungShield is currently being studied in a hospital setting to determine its efficacy for reducing infection and pain. Infection in endotracheal tubes is a common
Slide 22: Key Statistics
OTC QB : NAOV ● Ticker: NAOV ● Exchange: OTC Q B ● Share Price ( 9 / 8 / 17 ): $ 5.80 ● Common Shares Outstanding: 2.6 M ● Preferred Shares: 1.9 M ● Fiscal year - end: December 3 1 22 Key Statistics
Slide 23: Investment Summary
OTC QB : NAOV 23 Investment Summary x Potential breakthrough medical platform and devices – now entering commercial stage x Extensive existing and growing clinical evidence and regulatory approvals x Addresses multi - billion $ markets - catheter infections, pain relief & wound healing x New senior
Slide 24: Investor Relations Contacts
Investor Relations Contact s : Crescendo Communications / David Waldman NAOV@crescendo - ir.com / 212 - 671 - 102 1 Hayden IR / Brett Maas brett@haydenir.com / 646 - 536 - 7331 Company Contact: NanoVibronix Inc. Email: info@nanovibronix.com Phone: 914 - 233 - 3004 Thank You